FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1484335957> ?p ?o ?g. }

• W1484335957 abstract "Introduction: Several multi-gene expression based assays have been developed to assess the prognosis and predict response to endocrine treatments in early stage hormone receptor positive (HR+) breast cancer. Although a significant number of patients with metastatic ER+ disease will not respond to endocrine treatments, molecular assays to predict response in this setting are limited. In addition, tissue specimens of metastatic lesions for molecular studies are not always available. In this study we sought to identify a molecular profile in the primary tumors of patients who developed disease recurrence that could predict response to endocrine treatment in metastatic disease. Methods: We used the primary breast tumor samples from a subgroup of patients participating in the randomized phase III CONFIRM trial, which compared 500mg versus 250mg of fulvestrant in post-menopausal women with HR+ advanced breast cancer. Formalin- fixed paraffin embedded tumors were collected from 130 of the participants and were centrally reviewed for ER, PR, HER2 and Ki67. RNA was sufficient for gene expression profiling in 112 of the cases using the NuGEN Ovation FFPE WTA System and Affymetrix HTA 2.0 GeneChip. The majority of the patients in this analysis developed metastatic disease during adjuvant endocrine treatment (N=55) or had de-novo metastatic disease (N=39) versus relapse after adjuvant treatment (N=18). The association between gene expression and progression free survival (PFS) was investigated using a multivariate Cox proportional hazard model adjusting for statistically significant clinicopatholgical factors. In addition we performed pathway-level analysis and evaluated the PAM50 subtype predictor and Risk of Relapse (ROR) score. Results: The median PFS was 8 months in our cohort. HER2 level by immunohistochemistry above 1+, high PR level, defined as Allred score of above 6, and Ki67 of above 50% were significantly associated with PFS and were included in the multivariate model. Dose of fulvestrant was not associated with PFS in this cohort. We identified a signature of 25 genes that is inversely associated with PFS on fulvestrant treatment (FDR 20%). When compared to other published datasets of breast cancer tumors, these genes are enriched in tumors with poor outcome and triple negative cancers. Pathway analysis revealed an association between activation of the EGFR pathway and decreased PFS (P=0.01). PAM50 subtypes varied with the luminal subtype being the most common (65%) and were generally concordant with the clinical subtype. However, we did not detect a significant trend between PAM50 subtype or ROR score and PFS or overall survival. Conclusions: In this cohort of patients with early and de-novo metastatic disease we identified a gene signature in the primary tumors that is associated with decreased response to fulvestrant treatment in metastatic disease. This signature warrants further validation to determine it’s predictive value and potential to assist in treatment decision making for patients with HR+ metastatic disease. Citation Format: Rinath M Jeselsohn, William T Barry, Jin Zhao, Gilles Buchwalter, Cristina Guarducci, Ilenia Migliaccio, Chiara Biagioni, Martina Bonechi, Naomi Laing, Yuri Rukazenkov, Eric P Winer, Myles Brown, Angelo Di Leo, Luca Malorni. TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S1-01." @default.
• W1484335957 created "2016-06-24" @default.
• W1484335957 creator A5012991748 @default.
• W1484335957 creator A5018575107 @default.
• W1484335957 creator A5020813615 @default.
• W1484335957 creator A5027205195 @default.
• W1484335957 creator A5033532061 @default.
• W1484335957 creator A5041495974 @default.
• W1484335957 creator A5051714606 @default.
• W1484335957 creator A5054811688 @default.
• W1484335957 creator A5059871464 @default.
• W1484335957 creator A5060682631 @default.
• W1484335957 creator A5070245248 @default.
• W1484335957 creator A5075662505 @default.
• W1484335957 creator A5089361418 @default.
• W1484335957 creator A5090909467 @default.
• W1484335957 date "2015-04-30" @default.
• W1484335957 modified "2023-09-25" @default.
• W1484335957 title "Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant" @default.
• W1484335957 doi "https://doi.org/10.1158/1538-7445.sabcs14-s1-01" @default.
• W1484335957 hasPublicationYear "2015" @default.
• W1484335957 type Work @default.
• W1484335957 sameAs 1484335957 @default.
• W1484335957 citedByCount "0" @default.
• W1484335957 crossrefType "proceedings-article" @default.
• W1484335957 hasAuthorship W1484335957A5012991748 @default.
• W1484335957 hasAuthorship W1484335957A5018575107 @default.
• W1484335957 hasAuthorship W1484335957A5020813615 @default.
• W1484335957 hasAuthorship W1484335957A5027205195 @default.
• W1484335957 hasAuthorship W1484335957A5033532061 @default.
• W1484335957 hasAuthorship W1484335957A5041495974 @default.
• W1484335957 hasAuthorship W1484335957A5051714606 @default.
• W1484335957 hasAuthorship W1484335957A5054811688 @default.
• W1484335957 hasAuthorship W1484335957A5059871464 @default.
• W1484335957 hasAuthorship W1484335957A5060682631 @default.
• W1484335957 hasAuthorship W1484335957A5070245248 @default.
• W1484335957 hasAuthorship W1484335957A5075662505 @default.
• W1484335957 hasAuthorship W1484335957A5089361418 @default.
• W1484335957 hasAuthorship W1484335957A5090909467 @default.
• W1484335957 hasConcept C121608353 @default.
• W1484335957 hasConcept C126322002 @default.
• W1484335957 hasConcept C143998085 @default.
• W1484335957 hasConcept C207103383 @default.
• W1484335957 hasConcept C2775930923 @default.
• W1484335957 hasConcept C2777176818 @default.
• W1484335957 hasConcept C2777863537 @default.
• W1484335957 hasConcept C2780482068 @default.
• W1484335957 hasConcept C44249647 @default.
• W1484335957 hasConcept C50382708 @default.
• W1484335957 hasConcept C530470458 @default.
• W1484335957 hasConcept C71924100 @default.
• W1484335957 hasConceptScore W1484335957C121608353 @default.
• W1484335957 hasConceptScore W1484335957C126322002 @default.
• W1484335957 hasConceptScore W1484335957C143998085 @default.
• W1484335957 hasConceptScore W1484335957C207103383 @default.
• W1484335957 hasConceptScore W1484335957C2775930923 @default.
• W1484335957 hasConceptScore W1484335957C2777176818 @default.
• W1484335957 hasConceptScore W1484335957C2777863537 @default.
• W1484335957 hasConceptScore W1484335957C2780482068 @default.
• W1484335957 hasConceptScore W1484335957C44249647 @default.
• W1484335957 hasConceptScore W1484335957C50382708 @default.
• W1484335957 hasConceptScore W1484335957C530470458 @default.
• W1484335957 hasConceptScore W1484335957C71924100 @default.
• W1484335957 hasLocation W14843359571 @default.
• W1484335957 hasOpenAccess W1484335957 @default.
• W1484335957 hasPrimaryLocation W14843359571 @default.
• W1484335957 hasRelatedWork W10148955 @default.
• W1484335957 hasRelatedWork W11161530 @default.
• W1484335957 hasRelatedWork W12242190 @default.
• W1484335957 hasRelatedWork W13154270 @default.
• W1484335957 hasRelatedWork W16909223 @default.
• W1484335957 hasRelatedWork W19152528 @default.
• W1484335957 hasRelatedWork W20132274 @default.
• W1484335957 hasRelatedWork W20667999 @default.
• W1484335957 hasRelatedWork W2422317 @default.
• W1484335957 hasRelatedWork W4185548 @default.
• W1484335957 isParatext "false" @default.
• W1484335957 isRetracted "false" @default.
• W1484335957 magId "1484335957" @default.
• W1484335957 workType "article" @default.